157 related articles for article (PubMed ID: 36111610)
1. Divergence of mutational signatures in association with breast cancer subtype.
Perry G; Dadiani M; Kahana-Edwin S; Pavlovski A; Markus B; Hornung G; Balint-Lahat N; Yosepovich A; Hout-Siloni G; Jacob-Hirsch J; Sklair-Levy M; Friedman E; Barshack I; Kaufman B; Gal-Yam EN; Paluch-Shimon S
Mol Carcinog; 2022 Nov; 61(11):1056-1070. PubMed ID: 36111610
[TBL] [Abstract][Full Text] [Related]
2. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutational profiles and germline polygenic risk scores in human cancer.
Liu Y; Gusev A; Heng YJ; Alexandrov LB; Kraft P
Genome Med; 2022 Feb; 14(1):14. PubMed ID: 35144655
[TBL] [Abstract][Full Text] [Related]
4. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
5. Modeling clinical and molecular covariates of mutational process activity in cancer.
Robinson W; Sharan R; Leiserson MDM
Bioinformatics; 2019 Jul; 35(14):i492-i500. PubMed ID: 31510643
[TBL] [Abstract][Full Text] [Related]
6. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies.
Degasperi A; Amarante TD; Czarnecki J; Shooter S; Zou X; Glodzik D; Morganella S; Nanda AS; Badja C; Koh G; Momen SE; Georgakopoulos-Soares I; Dias JML; Young J; Memari Y; Davies H; Nik-Zainal S
Nat Cancer; 2020 Feb; 1(2):249-263. PubMed ID: 32118208
[No Abstract] [Full Text] [Related]
7. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
8. Whole exome sequencing-based analysis to identify DNA damage repair deficiency as a major contributor to gliomagenesis in adult diffuse gliomas.
Ülgen E; Can Ö; Bilguvar K; Oktay Y; Akyerli CB; Danyeli AE; Yakıcıer MC; Sezerman OU; Pamir MN; Özduman K
J Neurosurg; 2019 Apr; 132(5):1435-1446. PubMed ID: 30952131
[TBL] [Abstract][Full Text] [Related]
9. The topography of mutational processes in breast cancer genomes.
Morganella S; Alexandrov LB; Glodzik D; Zou X; Davies H; Staaf J; Sieuwerts AM; Brinkman AB; Martin S; Ramakrishna M; Butler A; Kim HY; Borg Å; Sotiriou C; Futreal PA; Campbell PJ; Span PN; Van Laere S; Lakhani SR; Eyfjord JE; Thompson AM; Stunnenberg HG; van de Vijver MJ; Martens JW; Børresen-Dale AL; Richardson AL; Kong G; Thomas G; Sale J; Rada C; Stratton MR; Birney E; Nik-Zainal S
Nat Commun; 2016 May; 7():11383. PubMed ID: 27136393
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
[TBL] [Abstract][Full Text] [Related]
11. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
[TBL] [Abstract][Full Text] [Related]
12. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
Wang S; Pitt JJ; Zheng Y; Yoshimatsu TF; Gao G; Sanni A; Oluwasola O; Ajani M; Fitzgerald D; Odetunde A; Khramtsova G; Hurley I; Popoola A; Falusi A; Ogundiran T; Obafunwa J; Ojengbede O; Ibrahim N; Barretina J; White KP; Huo D; Olopade OI
Int J Cancer; 2019 Dec; 145(12):3321-3333. PubMed ID: 31173346
[TBL] [Abstract][Full Text] [Related]
13. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
14. Distinct genetic landscape and a low response to doxorubicin in a luminal-A breast cancer cell line of Pakistani origin.
Shakeel M; Khan SA; Mughal AJ; Irfan M; Hoessli DC; Choudhary MI; Aurongzeb M; Khan IA
Mol Biol Rep; 2021 Oct; 48(10):6821-6829. PubMed ID: 34495459
[TBL] [Abstract][Full Text] [Related]
15. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
[TBL] [Abstract][Full Text] [Related]
16. A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.
Liu JC; Egan SE; Zacksenhaus E
Oncotarget; 2013 Aug; 4(8):1317-28. PubMed ID: 23945331
[TBL] [Abstract][Full Text] [Related]
17. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
18. Influence network model uncovers relations between biological processes and mutational signatures.
Amgalan B; Wojtowicz D; Kim YA; Przytycka TM
Genome Med; 2023 Mar; 15(1):15. PubMed ID: 36879282
[TBL] [Abstract][Full Text] [Related]
19. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
20. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Angus L; Smid M; Wilting SM; van Riet J; Van Hoeck A; Nguyen L; Nik-Zainal S; Steenbruggen TG; Tjan-Heijnen VCG; Labots M; van Riel JMGH; Bloemendal HJ; Steeghs N; Lolkema MP; Voest EE; van de Werken HJG; Jager A; Cuppen E; Sleijfer S; Martens JWM
Nat Genet; 2019 Oct; 51(10):1450-1458. PubMed ID: 31570896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
